Cas:16833-17-3 butyl 3-[4-[(4-methoxyphenyl)methylideneamino]phenyl]prop-2-enoate manufacturer & supplier

We serve Chemical Name:butyl 3-[4-[(4-methoxyphenyl)methylideneamino]phenyl]prop-2-enoate CAS:16833-17-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

butyl 3-[4-[(4-methoxyphenyl)methylideneamino]phenyl]prop-2-enoate

Chemical Name:butyl 3-[4-[(4-methoxyphenyl)methylideneamino]phenyl]prop-2-enoate
CAS.NO:16833-17-3
Synonyms:Butyl 4-[(p-Anisylidene)amino]cinnamate;4-[(4-METHOXYBENZYLIDENE)AMINO]CINNAMIC ACID N-BUTYL ESTER;Butyl 4-[(4-Methoxybenzylidene)amino]cinnamate;Butyl-p-anisylidene-p’-aminocinnamate;4-(p-Anisalamino)cinnamic Acid Butyl Ester;4-[(p-Anisylidene)amino]cinnamic Acid Butyl Ester;4-[(4-Methoxybenzylidene)amino]cinnamic Acid Butyl Ester
Molecular Formula:C21H23NO3
Molecular Weight:337.41200
HS Code:2925290090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:496.9ºC at 760 mmHg
Density:1.03g/cm3
Index of Refraction:1.527
PSA:47.89000
Exact Mass:337.16800
LogP:4.80230

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like Butyl 4-[(p-Anisylidene)amino]cinnamate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-[(4-Methoxybenzylidene)amino]cinnamic Acid Butyl Ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Butyl 4-[(4-Methoxybenzylidene)amino]cinnamate Use and application,4-(p-Anisalamino)cinnamic Acid Butyl Ester technical grade,usp/ep/jp grade.


Related News: AstraZeneca Plc said on Monday that its cancer drug met the main goal of delaying the progression of a form of lung cancer. butyl 3-[4-[(4-methoxyphenyl)methylideneamino]phenyl]prop-2-enoate manufacturer ��We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,�� said Ed Damiano, President and CEO of Beta Bionics. ��We are partuclarly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.�� butyl 3-[4-[(4-methoxyphenyl)methylideneamino]phenyl]prop-2-enoate supplier AstraZeneca Plc said on Monday that its cancer drug met the main goal of delaying the progression of a form of lung cancer. butyl 3-[4-[(4-methoxyphenyl)methylideneamino]phenyl]prop-2-enoate vendor New Zealand on Sunday became the latest country to impose restrictions on travelers from mainland China, saying it would deny entry to visitors departing from or transiting through the mainland for two weeks starting on Monday. butyl 3-[4-[(4-methoxyphenyl)methylideneamino]phenyl]prop-2-enoate factory Madeleine Roche, Associate Pharmaceutical Analyst at GlobalData, comments: ��Within the top 20 global companies that spent the most on R&D in 2018, the top spender �C despite having the second smallest annual revenue of the group at $15.28 billion �C is Celgene, whose R&D spend was equal to 37% of its annual revenue.